<MedlineCitation Status="Completed">
<MedlineID>10011053</MedlineID>
<PMID>369492</PMID>
<DateCreated>
<Year>1979</Year>
<Month>04</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>04</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0003-9950</ISSN>
<JournalIssue>
<Volume>97</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1979</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>HLA antigens in ocular cicatricial pemphigoid.</ArticleTitle>
<Pagination>
<MedlinePgn>479</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>HLA antigen frequencies were studied in 45 patients with ocular cicatricial pemphigoid. HLA-B12 was found to have an increased frequency of 44.4% in patients with ocular cicatricial pemphigoid, which was statistically significant when compared with a frequency of 19.6% in the control population (P less than .001 or P less than .031 when corrected for the number of antigens tested). The results of this study suggest that there is an immunogenetic susceptibility to the development of ocular cicatricial pemphigoid.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Mondino</LastName>
<ForeName>B J</ForeName>
<Initials>BJ</Initials>
</Author>
<Author>
<LastName>Brown</LastName>
<ForeName>S I</ForeName>
<Initials>SI</Initials>
</Author>
<Author>
<LastName>Rabin</LastName>
<ForeName>B S</ForeName>
<Initials>BS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Arch Ophthalmol</MedlineTA>
<NlmUniqueID>7706534</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>HLA Antigens</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Eye Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>HLA Antigens</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Skin Diseases, Vesiculobullous</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
